当前位置: X-MOL 学术Expert Rev. Pharmacoecon. Outcomes Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management.
Expert Review of Pharmacoeconomics & Outcomes Research ( IF 1.8 ) Pub Date : 2019-05-10 , DOI: 10.1080/14737167.2019.1612242
Yanina Jackson 1 , Ellen Janssen 2 , Ryan Fischer 3 , Katherine Beaverson 4 , Jane Loftus 5 , Kate Betteridge 5 , Stephanie Rhoten 6 , Emuella Flood 2 , Mark Lundie 7
Affiliation  

Introduction: There is a growing trend of using patient preference studies to help incorporate the patient perspective into clinical drug development, care management, and health-care decision-making. Collecting and interpreting patient preference data is integral to multi-stakeholder engagement, patient-centric drug development, and clinical care management. Operationally, challenges exist in understanding 'when' and 'how' to embark on patient preference studies. This review will provide a brief overview of stated-preference methods, discuss applications throughout the clinical drug development and care management, and highlight how preference studies serve as a powerful tool for quantifying patient experiences for better outcomes. Areas covered: We present case studies to complement the different applications of stated-preference methods in clinical drug development and care management. We discuss the applications of preference data to help inform evidence-based patient advocacy, clinical development strategy, operational feasibility, regulator benefit-risk assessments, health technology assessments, and clinical decision-making. Expert commentary: Patient preference studies can serve as a powerful tool to engage patients and their communities as well as quantify the patient voice across different stages of clinical drug development and care management to support patient-centric health-care decision-making. It is expected that the application of these strategies will quickly advance in the coming years.

中文翻译:

从临床药物开发到临床护理管理,患者偏爱研究在医疗保健决策中的作用不断演变。

简介:使用患者偏爱研究来帮助将患者观点纳入临床药物开发,护理管理和医疗保健决策的趋势正在增长。收集和解释患者偏好数据是多利益相关方参与,以患者为中心的药物开发和临床护理管理不可或缺的部分。在操作上,在理解“何时”和“如何”着手进行患者偏好研究方面存在挑战。这篇综述将简要介绍陈述的首选方法,讨论整个临床药物开发和护理管理中的应用,并重点介绍偏好研究如何作为量化患者经验以获得更好结果的有力工具。涵盖领域:我们提供案例研究,以补充在临床药物开发和护理管理中陈述优选方法的不同应用。我们讨论了偏好数据的应用,以帮助告知基于证据的患者主张,临床开发策略,操作可行性,监管者利益风险评估,健康技术评估以及临床决策。专家评论:患者偏爱研究可以作为吸引患者及其社区的有力工具,并在临床药物开发和护理管理的不同阶段量化患者的声音,以支持以患者为中心的医疗保健决策。预计这些策略的应用将在未来几年迅速发展。我们讨论了偏好数据的应用,以帮助告知基于证据的患者主张,临床开发策略,操作可行性,监管者利益风险评估,健康技术评估以及临床决策。专家评论:患者偏爱研究可以作为吸引患者及其社区的有力工具,并在临床药物开发和护理管理的不同阶段量化患者的声音,以支持以患者为中心的医疗保健决策。预计这些策略的应用将在未来几年迅速发展。我们讨论了偏好数据的应用,以帮助告知基于证据的患者主张,临床开发策略,操作可行性,监管者利益风险评估,健康技术评估以及临床决策。专家评论:患者偏爱研究可以作为吸引患者及其社区的有力工具,并在临床药物开发和护理管理的不同阶段量化患者的声音,以支持以患者为中心的医疗保健决策。预计这些策略的应用将在未来几年迅速发展。专家评论:患者偏爱研究可以作为吸引患者及其社区的有力工具,并在临床药物开发和护理管理的不同阶段量化患者的声音,以支持以患者为中心的医疗保健决策。预计这些策略的应用将在未来几年迅速发展。专家评论:患者偏爱研究可以作为吸引患者及其社区的有力工具,并在临床药物开发和护理管理的不同阶段量化患者的声音,以支持以患者为中心的医疗保健决策。预计这些策略的应用将在未来几年迅速发展。
更新日期:2019-11-01
down
wechat
bug